A recent study showed that FASN inhibition increases mitochondrial priming and enhances breast cancer cell sensitivity to BCL2-targeting BH3 mimetics which may directly activate the apoptotic machinery and generate more potent and longer-lasting antitumor responses in a clinical setting51. This evidence concerns the gene BCL2 and breast carcinoma.